ArticlePloS one2026
Heterogeneous stock market responses to pharmaceutical policy events across subsectors and time scales: Evidence from China.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whether abnormal returns around different pharmaceutical policy events exhibit similar patterns, and whether these patterns vary across industry-index levels, return scales, and event windows, has received limited comparative examination within a unified analytical framework. This study examines six pharmaceutical policy events in China using the Shenwan first-level Pharmaceutical and Biotechnology Index and six Shenwan second-level pharmaceutical sub-sector indices, with the CSI 300 Index as the market benchmark. Ensemble Empirical Mode Decomposition (EEMD) is used to reconstruct returns at multiple scales, and an event-study framework is applied to estimate abnormal returns (ARs) and cumulative abnormal returns (CARs). The results show that, within the events, industry indices, and event windows examined, policy objectives or policy-instrument attributes do not exhibit a consistent correspondence with observed abnormal-return patterns. Medium-frequency CARs were generally negative for both centralized procurement events, but centralized drug procurement showed broader negative accumulation across sub-sectors, whereas centralized procurement of high-value medical consumables showed greater sectoral differentiation. Although the clinical trial data self-inspection and verification event and the reform of the drug review and approval system both involved drug R&D and registration regulation, their abnormal-return patterns differed markedly, with the latter showing broadly positive medium-frequency CARs. The aggregate industry index may not fully capture underlying differences when sub-sector responses diverge substantially, and high- and medium-frequency CARs also differ in direction for some events and sub-sectors. In addition, the cumulative direction of CARs over wider event windows may differ from the trajectory of daily ARs following the policy announcement. Overall, generalizations based on policy categories, an aggregate industry index, or a single event window may overlook important differences in abnormal returns across industry-index levels, return scales, and temporal paths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.